BlackRock’s Aktis Oncology AKTS Stock Holding History

BlackRock’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.8M	Buy	+2,112,127	New	+$41M	﹤0.01%	2695

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock's AKTS Position: Q1 2026 in Review

BlackRock opened a new position in Aktis Oncology (AKTS) in Q1 2026: 2,112,127 shares worth $37.8M. The stake represents ﹤0.01% of the portfolio and ranks #2695 among its holdings.

69 funds tracked by Wall St. Rank hold AKTS as of Q1 2026.

BlackRock held 2,112,127 shares of Aktis Oncology worth $37.8M as of Q1 2026.
Aktis Oncology was a new BlackRock position in Q1 2026.
Aktis Oncology made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2695 holding.
69 funds tracked by Wall St. Rank held Aktis Oncology as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.